Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavgacı, Akif, Kula, Serdar, İncedere, Fatma, Terlemez, Semiha, Tunaoğlu, Fatma Sedef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012979/
https://www.ncbi.nlm.nih.gov/pubmed/36926146
http://dx.doi.org/10.5606/tgkdc.dergisi.2023.23748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012979/
https://www.ncbi.nlm.nih.gov/pubmed/36926146
http://dx.doi.org/10.5606/tgkdc.dergisi.2023.23748

Ejemplares similares